The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
New Hybrids of 4-Amino-2,3-polymethylene-quinoline and p-Tolylsulfonamide as Dual Inhibitors of Acetyl- and Butyrylcholinesterase and Potential Multifunctional Agents for Alzheimer’s Disease Treatment
Open accessAbstract
New hybrid compounds of 4-amino-2,3-polymethylene-quinoline containing different sizes of the aliphatic ring and linked to p-tolylsulfonamide with alkylene spacers of increasing length were synthesized as potential drugs for treatment of Alzheimer’s disease (AD). All compounds were potent inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with selectivity toward BChE. The lead compound 4-methyl-N-(5-(1,2,3,4-tetrahydro-acridin-9-ylamino)-pentyl)-benzenesulfonamide (7h) exhibited an IC50 (AChE) = 0.131 ± 0.01 µM (five times more potent than tacrine), IC50(BChE) = 0.0680 ± 0.0014 µM, and 17.5 ± 1.5% propidium displacement at 20 µM. The compounds possessed low activity against carboxylesterase, indicating a likely absence of unwanted drug-drug interactions in clinical use. Kinetics studies were consistent with mixed-type reversible inhibition of both cholinesterases. Molecular docking demonstrated dual binding sites of the conjugates in AChE and clarified the differences in the structure-activity relationships for AChE and BChE inhibition. The conjugates could bind to the AChE peripheral anionic site and displace propidium, indicating their potential to block AChE-induced β-amyloid aggregation, thereby exerting a disease-modifying effect. All compounds demonstrated low antioxidant activity. Computational ADMET profiles predicted that all compounds would have good intestinal absorption, medium blood-brain barrier permeability, and medium cardiac toxicity risk. Overall, the results indicate that the novel conjugates show promise for further development and optimization as multitarget anti-AD agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting both AChE and Butyrylcholinesterase (BuChE) not only alleviates cognitive impairment in AD patients by increasing ACh levels but also serves as a disease-modifying agent, delaying the formation of Aβ plaques.527–529”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [528]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
Antioxidant activity applying an improved ABTS radical cation decolorization assay
Re, R., Pellegrini, N., Proteggente, A., Pannala, A., Yang, M., & Rice-Evans, C. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00315-3 · Cited by 26,165
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
General atomic and molecular electronic structure system
Schmidt, M. W., Baldridge, K. K., Boatz, J. A., Elbert, S. T., Gordon, M. S., Jensen, J. H., Koseki, S., Matsunaga, N., Nguyen, K. A., Su, S., et al. (1993) · Journal of Computational Chemistry · doi:10.1002/jcc.540141112 · Cited by 20,204
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Sussman, J. L., Harel, M., Frolow, F., Oefner, C., Goldman, A., Toker, L., & Silman, I. (1991) · Science · doi:10.1126/science.1678899 · Cited by 2,707 · cited 2×
“BChE has a wider gorge than AChE without a pronounced narrowing to separate the PAS and CAS, and most of the BChE gorge residues that are aromatic in AChE are replaced in BChE with aliphatic ones [86].”
BackgroundQuantifying the chemical beauty of drugs
Bickerton, G. R., Paolini, G. V., Besnard, J., Muresan, S., & Hopkins, A. L. (2012) · Nature Chemistry · doi:10.1038/nchem.1243 · Cited by 2,242
Perry, E. K., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P. H., & Perry, R. H. (1978) · BMJ · doi:10.1136/bmj.2.6150.1457 · Cited by 2,042 · cited 1×
“These processes most severely affect the cholinergic system and result in a progressive decrease in levels of the neurotransmitter acetylcholine (ACh) [6], which in turn produces the memory and cognitive deficits characteristic for patients with AD [7].”
BackgroundCholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · cited 1×
“However, it is obvious now that AD is a complex, multifactorial disorder and that advanced age is the main risk factor [2,3].”
Background2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands
Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,356 · cited 1×
“X-ray structures of human AChE in apo-form and co-crystallized with different ligands (PDB: 4EY4–4EY7) [98] and an optimized X-ray structure of human BChE (PDB: 1P0I) [99,100] were used for molecular docking.”
MethodAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Inestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101 · cited 2×
“It has been found that PAS ligands, such as propidium, block AChE-induced Aβ aggregation by physically hampering Aβ binding to the enzyme surface [26,27,30].”
BackgroundRole of oxidative stress in Alzheimer’s disease
HUANG, W.-J., ZHANG, X., & CHEN, W.-W. (2016) · Biomedical Reports · doi:10.3892/br.2016.630 · Cited by 1,023
Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products
Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J. C., & Nachon, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210241200 · Cited by 840
On the Nonorthogonality Problem
(1970) · Advances in Quantum Chemistry · doi:10.1016/s0065-3276(08)60339-1 · Cited by 777
Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 734 · cited 1×
“Selective inhibitors of BChE can increase the brain level of acetylcholine and enhance cognitive functions in rodents without the usual side effects typical of AChE inhibitors [17,18,21].”
BackgroundTreatment of Alzheimer's disease; current status and new perspectives
scarpini, E., Schelterns, P., & Feldman, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00502-7 · Cited by 721
Sushko, I., Novotarskyi, S., Körner, R., Pandey, A. K., Rupp, M., Teetz, W., Brandmaier, S., Abdelaziz, A., Prokopenko, V. V., Tanchuk, V. Y., et al. (2011) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-011-9440-2 · Cited by 686
Self-citationTargeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654 · cited 1×
“It is believed that compounds inhibiting both cholinesterases increase the efficiency of treatment [19,20,22].”
BackgroundSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies
Bartolini, M., Bertucci, C., Cavrini, V., & Andrisano, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01514-9 · Cited by 568
A Structural Motif of Acetylcholinesterase That Promotes Amyloid β-Peptide Fibril Formation
De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., & Inestrosa, N. C. (2001) · Biochemistry · doi:10.1021/bi0101392 · Cited by 413 · cited 3×
“A decrease in propidium fluorescence in the presence of test compounds indicates that they are able to displace propidium and bind to the PAS of AChE, suggesting that they would thereby block the AChE-mediated aggregation of β-amyloid [24,27,29,33].”
BackgroundSupercomputer Lomonosov-2: Large Scale, Deep Monitoring and Fine Analytics for the User Community
(2019) · Supercomputing Frontiers and Innovations · doi:10.14529/jsfi190201 · Cited by 392
Cholinesterases: New Roles in Brain Function and in Alzheimer's Disease
Giacobini, E. (2003) · Neurochemical Research · doi:10.1023/a:1022869222652 · Cited by 371 · cited 2×
“However, with progression of AD, the activity of AChE decreases while the activity of BChE gradually increases [13,15,16].”
BackgroundTaylor, P., & Lappi, S. (1975) · Biochemistry · doi:10.1021/bi00680a029 · Cited by 364 · cited 2×
“Propidium is a selective ligand for the PAS of AChE responsible for the Aβ binding [24,29,30,93], which showed a significant decrease in AChE-induced Aβ aggregation (82% at 100 μM) [26].”
BackgroundMethodCholinesterases: Roles in the Brain During Health and Disease
Ballard, C., Greig, N., Guillozet-Bongaarts, A., Enz, A., & Darvesh, S. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367838 · Cited by 350 · cited 1×
“However, with progression of AD, the activity of AChE decreases while the activity of BChE gradually increases [13,15,16].”
BackgroundHighly Potent, Selective, and Low Cost Bis-tetrahydroaminacrine Inhibitors of Acetylcholinesterase
Pang, Y.-P., Quiram, P., Jelacic, T., Hong, F., & Brimijoin, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.39.23646 · Cited by 344 · cited 1×
“The results are consistent with the known data that, in contrast to extremely powerful bis-tacrine inhibitors [78], tacrine-based hybrid compounds linking tacrine with an uncharged aromatic group had anti-AChE activities comparable to that of tacrine [79,80].”
ResultA review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease
Nordberg, A., Ballard, C., Bullock, R., Darreh-Shori, T., & Somogyi, M. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01412 · Cited by 323 · cited 1×
“It is believed that compounds inhibiting both cholinesterases increase the efficiency of treatment [19,20,22].”
BackgroundFernández-Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodríguez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 268
Amyloid–cholinesterase interactions: Implications for Alzheimer’s disease
Inestrosa, N. C., Dinamarca, M. C., & Alvarez, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06238.x · Cited by 261
Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia
Mesulam, ‐., & Geula, C. (1994) · Annals of Neurology · doi:10.1002/ana.410360506 · Cited by 258 · cited 2×
“However, with progression of AD, the activity of AChE decreases while the activity of BChE gradually increases [13,15,16].”
BackgroundSulfonamide derivatives as multi-target agents for complex diseases
Apaydın, S., & Török, M. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.06.041 · Cited by 256 · cited 1×
“Sulfonamides are widely utilized in various pharmaceutical applications due to their therapeutic versatility that encompasses antibacterial, antiviral, antimalarial, antifungal, anticancer, antidepressant, and other properties [58,59].”
BackgroundSaxena, A., Redman, A. M. G., Jiang, X., Lockridge, O., & Doctor, B. P. (1997) · Biochemistry · doi:10.1021/bi971425+ · Cited by 248 · cited 2×
“BChE has a wider gorge than AChE without a pronounced narrowing to separate the PAS and CAS, and most of the BChE gorge residues that are aromatic in AChE are replaced in BChE with aliphatic ones [86].”
BackgroundThe Multifactorial Nature of Alzheimer's Disease for Developing Potential Therapeutics
Carreiras, M., Mendes, E., Perry, M., Francisco, A., & Marco-Contelles, J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990135 · Cited by 240 · cited 1×
“However, it is obvious now that AD is a complex, multifactorial disorder and that advanced age is the main risk factor [2,3].”
BackgroundMulti-Target-Directed Ligands in Alzheimer's Disease Treatment
Bajda, M., Guzior, N., Ignasik, M., & Malawska, B. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711797535245 · Cited by 240
A molecular approach in drug development for Alzheimer’s disease
Agatonovic-Kustrin, S., Kettle, C., & Morton, D. W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.147 · Cited by 233 · cited 1×
“However, although these medications can temporarily reduce the development of AD symptoms, they cannot stop the progression of neurodegeneration [8,14].”
BackgroundMuñoz-Ruiz, P., Rubio, L., García-Palomero, E., Dorronsoro, I., del Monte-Millán, M., Valenzuela, R., Usán, P., de Austria, C., Bartolini, M., Andrisano, V., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0503289 · Cited by 219
Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer's Disease
Darvesh, S. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160404120542 · Cited by 213
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
Li, Q., He, S., Chen, Y., Feng, F., Qu, W., & Sun, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.031 · Cited by 202
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Swaminathan, S., Shen, L., Foroud, T. M., Hakonarson, H., Huentelman, M. J., Aisen, P. S., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.19 · Cited by 200 · cited 1×
“BChE is also involved in the formation and/or maturation of Aβ plaques and thereby contributes to the pathogenesis of AD [15,35].”
BackgroundA review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease
Sameem, B., Saeedi, M., Mahdavi, M., & Shafiee, A. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.060 · Cited by 194
Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas
Supuran, C. T. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1523897 · Cited by 182
Ismaili, L., Refouvelet, B., Benchekroun, M., Brogi, S., Brindisi, M., Gemma, S., Campiani, G., Filipic, S., Agbaba, D., Esteban, G., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.003 · Cited by 178
Furukawa‐Hibi, Y., Alkam, T., Nitta, A., Matsuyama, A., Mizoguchi, H., Suzuki, K., Moussaoui, S. M., Yu, Q.-S., Greig, N. H., Nagai, T., et al. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.07.035 · Cited by 164 · cited 1×
“Selective inhibitors of BChE can increase the brain level of acetylcholine and enhance cognitive functions in rodents without the usual side effects typical of AChE inhibitors [17,18,21].”
BackgroundDevelopment of an in-vivo active reversible butyrylcholinesterase inhibitor
Košak, U., Brus, B., Knez, D., Šink, R., Žakelj, S., Trontelj, J., Pišlar, A., Šlenc, J., Gobec, M., Živin, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39495 · Cited by 163 · cited 2×
“Selective inhibitors of BChE can increase the brain level of acetylcholine and enhance cognitive functions in rodents without the usual side effects typical of AChE inhibitors [17,18,21].”
BackgroundOset‐Gasque, M. J., & Marco‐Contelles, J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00069 · Cited by 160
Nocentini, A., & Supuran, C. T. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1651289 · Cited by 160
Darvesh, S., Cash, M. K., Reid, G. A., Martin, E. V., Mitnitski, A., & Geula, C. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31823cc7a6 · Cited by 159
Molecular Dynamics of Acetylcholinesterase Dimer Complexed with Tacrine
Wlodek, S. T., Clark, T. W., Scott, L. R., & McCammon, J. A. (1997) · Journal of the American Chemical Society · doi:10.1021/ja971226d · Cited by 158 · cited 1×
“The AChE gorge is lined with aromatic residues that favor binding of positively charged substrates/inhibitors, and the dynamically changing radius of the bottleneck determines the kinetics of binding; in particular, slow-binding inhibition [87,88].”
BackgroundPrediction of human intestinal absorption of drug compounds
Radchenko, E. V., Дябина, А. С., Palyulin, V. A., & Zefirov, N. S. (2016) · Russian Chemical Bulletin · doi:10.1007/s11172-016-1340-0 · Cited by 137
Self-citationNovel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease
Martínez, A., & Castro, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.1.1 · Cited by 132 · cited 2×
“The cholinergic therapy of AD was originally directed primarily toward the inhibition of AChE [11,14].”
BackgroundAnti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998–2018)
Mishra, P., Kumar, A., & Panda, G. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.025 · Cited by 130
Bonardi, A., Nocentini, A., Bua, S., Combs, J. E., Lomelino, C. L., Andring, J. T., Lucarini, L., Sgambellone, S., Masini, E., McKENNA, R. V., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00733 · Cited by 129
Supuran, C. T. (2017) · Molecules · doi:10.3390/molecules22101642 · Cited by 126 · cited 1×
“Sulfonamides are widely utilized in various pharmaceutical applications due to their therapeutic versatility that encompasses antibacterial, antiviral, antimalarial, antifungal, anticancer, antidepressant, and other properties [58,59].”
BackgroundAlFadly, E. D., Elzahhar, P. A., Tramarin, A., Elkazaz, S., Shaltout, H. A., Abu-Serie, M. M., Janočková, J., Soukup, O., Ghareeb, D. A., EL‐Yazbi, A. F., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.012 · Cited by 115
Saxena, A., Redman, A. M. G., Jiang, X., Lockridge, O., & Doctor, B. P. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00014-9 · Cited by 110
Arce, M. P., Rodrı́guez-Franco, M. I., González-Muñoz, G. C., Pérez, C., López, B., Villarroya, M., López, M. G., Garcı́a, A. G., & Conde, S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900628z · Cited by 109 · cited 1×
“This observation has served as the basis for the fluorescent evaluation of competitive propidium displacement from the PAS of AChE as a screening method to assess the potential ability of compounds to bind PAS and thus block the pro-aggregation activity of AChE [28].”
MethodМахаева, Г. Ф., Lushchekina, S. V., Boltneva, N. P., Sokolov, V. B., Grigoriev, V. V., Serebryakova, O. G., Vikhareva, E. A., Aksinenko, A. Y., Barreto, G. E., Aliev, G., et al. (2015) · Scientific Reports · doi:10.1038/srep13164 · Cited by 108 · cited 1×
“These sources of BChE and CES were used because of their relatively low cost, high sequence identity to human enzymes [73,74,76], and the exploratory character of this work.”
MethodSelf-citationSawatzky, E., Wehle, S., Kling, B., Wendrich, J., Bringmann, G., Sotriffer, C., Heilmann, J., & Decker, M. W. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01674 · Cited by 108 · cited 1×
“This makes the BChE gorge more permissive to uncharged or even negatively charged substrates and inhibitors [89], and less prone to slow-binding inhibition than is the case with AChE [90,91].”
BackgroundButyrylcholinesterase and the cholinergic system
Reid, G. A., Chilukuri, N., & Darvesh, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2012.12.054 · Cited by 105 · cited 1×
“8), which terminate cholinergic neurotransmission by the hydrolysis of ACh [12].”
BackgroundZueva, I. V., Dias, J., Lushchekina, S. V., Semenov, V. E., Mukhamedyarov, M. A., Pashirova, T. N., Babaev, V. M., Nachon, F., Petrova, N. V., Faritovich, N. L., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.05.025 · Cited by 98 · cited 1×
“A decrease in propidium fluorescence in the presence of test compounds indicates that they are able to displace propidium and bind to the PAS of AChE, suggesting that they would thereby block the AChE-mediated aggregation of β-amyloid [24,27,29,33].”
BackgroundSelf-citationSulfonamides as multifunctional agents for Alzheimer’s disease
Bag, S., Tulsan, R., Sood, A., Cho, H., Redjeb, H., Zhou, W., LeVine, H., Török, B., & Török, M. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.12.006 · Cited by 96 · cited 1×
“Several sulfonamide-containing compounds exhibited promising Aβ self-assembly and cholinesterase inhibition, and in parallel showed good free radical scavenging properties [63].”
BackgroundSilva, M. D. F., Dias, K. S. T., Gontijo, V. S., Ortiz, C. J. C., & Viegas, C. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180111101843 · Cited by 96
Rosini, M., Simoni, E., Bartolini, M., Tarozzi, A., Matera, R., Milelli, A., Hrelia, P., Andrisano, V., Bolognesi, M. L., & Melchiorre, C. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.001 · Cited by 90
Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz‐Torrero, D., Ramírez, L., Viayna, E., Gómez, E., Isambert, N., Lavilla, R., et al. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.02.013 · Cited by 87
Multitarget Tacrine Hybrids with Neuroprotective Properties to Confront Alzheimer’s Disease
Špilovská, K., Korábečný, J., Nepovimová, E., Doležal, R., Mezeiová, E., Soukup, O., & Kuča, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026605666160927152728 · Cited by 86
Multifunctional Tacrine Derivatives in Alzheimer’s Disease
Minarini, A., Milelli, A., Simoni, E., Rosini, M., Bolognesi, M. L., Marchetti, C., & Tumiatti, V. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990136 · Cited by 85
Sterri, S. H., Johnsen, B. A., & Fonnum, F. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90579-9 · Cited by 84 · cited 1×
“The activity of CES was determined spectrophotometrically at 405 nm to monitor the release of 4-nitrophenol [95] in 0.”
MethodWu, W., Dai, Y.-C., Li, N., Dong, Z., Gu, T., Shi, Z., Xue, X., Tang, Y., & Duan, J. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1210139 · Cited by 80
Masson, P., Froment, M.-T., Fortier, P.-L., Visicchio, J.-E., Bartels, C. F., & Lockridge, O. (1998) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(98)00104-6 · Cited by 79 · cited 1×
“This makes the BChE gorge more permissive to uncharged or even negatively charged substrates and inhibitors [89], and less prone to slow-binding inhibition than is the case with AChE [90,91].”
BackgroundThe chemistry toolbox of multitarget-directed ligands for Alzheimer's disease
Mesiti, F., Chavarria, D., Gaspar, A., Alcaro, S., & Borges, F. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111572 · Cited by 79
Bartorelli, L., Giraldi, C., Saccardo, M., Cammarata, S., Bottini, G., Fasanaro, A. M., Trequattrini, A., & for the Upgrade Study Group (members are listed after Acknowledgements) (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65655 · Cited by 78
An update on drug treatment options of Alzheimer's disease
Allgaier, M., & Allgaier, C. (2014) · Frontiers in bioscience · doi:10.2741/4285 · Cited by 76
Махаева, Г. Ф., Ковалева, Н. В., Boltneva, N. P., Lushchekina, S. V., Рудакова, Е. В., Stupina, T. S., Terentiev, A. A., Serkov, I. V., Proshin, A. N., Radchenko, E. V., et al. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103387 · Cited by 75 · cited 1×
“Radical scavenging activity of the compounds was assessed using the ABTS radical decolorization assay [97] with some modifications [50].”
MethodSelf-citationTang, H., Zhao, L.-Z., Zhao, H., Huang, S., Zhong, S., Qin, J., Chen, Z., Huang, Z., & Liang, H. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.08.002 · Cited by 74
Organophosphorus compound esterase profiles as predictors of therapeutic and toxic effects
Махаева, Г. Ф., Radchenko, E. V., Palyulin, V. A., Рудакова, Е. В., Aksinenko, A. Y., Sokolov, V. B., Zefirov, N. S., & Richardson, R. J. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.10.012 · Cited by 73 · cited 1×
“These sources of BChE and CES were used because of their relatively low cost, high sequence identity to human enzymes [73,74,76], and the exploratory character of this work.”
MethodSelf-citationSynthesis and bioactivity of several new hetaryl sulfonamides
Taslımı, P., Sujayev, A. R., Mamedova, S. I., Kalın, P., Gülçın, İ., Sadeghian, N., Beydemir, Ş., Küfrevioğlu, Ö. İ., Alwasel, S. H., Farzaliyev, V., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1238367 · Cited by 70 · cited 2×
“The presence of antioxidant activity in a number of sulfonamide derivatives [66,68,69] prompted us to assess the antioxidant properties of the new hybrid compounds.”
BackgroundPrediction of blood-brain barrier permeability of organic compounds
Дябина, А. С., Radchenko, E. V., Palyulin, V. A., & Зефиров, Н. С. (2016) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672916050173 · Cited by 69
Self-citationEsterase profiles of organophosphorus compounds in vitro predict their behavior in vivo
Махаева, Г. Ф., Рудакова, Е. В., Serebryakova, O. G., Aksinenko, A. Y., Lushchekina, S. V., Бачурин, С. О., & Richardson, R. J. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.05.002 · Cited by 67 · cited 1×
“These sources of BChE and CES were used because of their relatively low cost, high sequence identity to human enzymes [73,74,76], and the exploratory character of this work.”
MethodSelf-citationKošak, U., Knez, D., Coquelle, N., Brus, B., Pišlar, A. H., Nachon, F., Brazzolotto, X., Kos, J., Colletier, J., & Gobec, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.032 · Cited by 67
Girek, M. K., & Szymański, P. (2018) · Chemical Papers · doi:10.1007/s11696-018-0590-8 · Cited by 67
Computer-aided estimation of the hERG-mediated cardiotoxicity risk of potential drug components
Radchenko, E. V., Рулев, Ю. А., Сафаньяев, А. Я., Palyulin, V. A., & Zefirov, N. S. (2017) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672917020107 · Cited by 66
Self-citationМахаева, Г. Ф., Boltneva, N. P., Lushchekina, S. V., Serebryakova, O. G., Stupina, T. S., Terentiev, A. A., Serkov, I. V., Proshin, A. N., Бачурин, С. О., & Richardson, R. J. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.031 · Cited by 62
Self-citationCholinesterase and carboxylesterase inhibitors as pharmacological agents
Махаева, Г. Ф., Рудакова, Е. В., Ковалева, Н. В., Lushchekina, S. V., Boltneva, N. P., Proshin, A. N., Shchegolkov, E. V., Burgart, Y. V., & Салоутин, В. И. (2019) · Russian Chemical Bulletin · doi:10.1007/s11172-019-2507-2 · Cited by 61 · cited 1×
“This confirms our previous finding [49,71].”
Self-citationМахаева, Г. Ф., Shevtsova, E. F., Boltneva, N. P., Lushchekina, S. V., Ковалева, Н. В., Рудакова, Е. В., Бачурин, С. О., & Richardson, R. J. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.020 · Cited by 58
Self-citationMasson, P., Lushchekina, S. V., Schopfer, L. M., & Lockridge, O. (2013) · Biochemical Journal · doi:10.1042/bj20130389 · Cited by 57
Self-citationTacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§
Milelli, A., Simone, A. D., Ticchi, N., Chen, H. H., Betari, N., Andrisano, V., & Tumiatti, V. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170309123920 · Cited by 53
Therapeutic Potential of Multifunctional Tacrine Analogues
Przybyłowska, M., Kowalski, S., Dzierzbicka, K., & Inkielewicz‐Stępniak, I. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180412091908 · Cited by 52
Multifunctional Hybrid Sulfonamides as Novel Therapeutic Agents for Alzheimer’s Disease
Swetha, R., Kumar, D., Gupta, S. K., Ganeshpurkar, A., Singh, R., Gutti, G., Kumar, D., Jana, S., Krishnamurthy, S., & Singh, S. K. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0106 · Cited by 50 · cited 1×
“In addition, quinoline-sulfonamide hybrids have been developed as potential multifunctional therapeutic agents for AD with high anti-AChE and anti-BChE activity; the lead compound in this series was shown to improve hippocampal-dependent working memory in a rat model [70].”
BackgroundPropidium—a Fluorescence Probe for a Peripheral Anionic Site on Acetylcholinesterase
Taylor, P., Lwebuga‐Mukasa, J. S., Lappi, S., & Rademacher, J. (1974) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13975-8 · Cited by 49 · cited 1×
“The ability of the test compounds to competitively displace propidium, a selective ligand of the PAS of AChE, was evaluated by the fluorescence method [93,96].”
MethodKharlamova, A. D., Lushchekina, S. V., Petrov, K. A., Kots, E. D., Nachon, F., Villard-Wandhammer, M., Zueva, I. V., Krejci, É., Reznik, V. S., Васильевич, З. В., et al. (2016) · Biochemical Journal · doi:10.1042/bcj20160084 · Cited by 47 · cited 1×
“This makes the BChE gorge more permissive to uncharged or even negatively charged substrates and inhibitors [89], and less prone to slow-binding inhibition than is the case with AChE [90,91].”
BackgroundSelf-citationKorábečný, J., Andrš, M., Nepovimová, E., Doležal, R., Babkova, K., Horova, A., Maliňák, D., Mezeiová, E., Górecki, L., Šepsová, V., et al. (2015) · Molecules · doi:10.3390/molecules201219836 · Cited by 45
Cholinesterases colocalize with sites of neurofibrillary degeneration in aged and Alzheimer's brains
Mor�n, M. A., Mufson, E. J., & Gómez‐Ramos, P. (1994) · Acta Neuropathologica · doi:10.1007/bf00296744 · Cited by 44
Махаева, Г. Ф., Radchenko, E. V., Baskin, I. I., Palyulin, V. A., Richardson, R. J., & Zefirov, N. S. (2012) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2012.679690 · Cited by 40
Self-citationSlow-binding inhibition of cholinesterases, pharmacological and toxicological relevance
Masson, P., & Lushchekina, S. V. (2016) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2016.02.010 · Cited by 40 · cited 1×
“The AChE gorge is lined with aromatic residues that favor binding of positively charged substrates/inhibitors, and the dynamically changing radius of the bottleneck determines the kinetics of binding; in particular, slow-binding inhibition [87,88].”
BackgroundSelf-citationSoyer, Z., Uysal, Ş., Parlar, S., Tarikogullari, A. H., & Alptüzün, V. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1226298 · Cited by 40
Role of Acetylcholinesterase in β-Amyloid Aggregation Studied by Accelerated Molecular Dynamics
Lushchekina, S. V., Kots, E. D., Novichkova, D. A., Petrov, K. A., & Masson, P. (2016) · BioNanoScience · doi:10.1007/s12668-016-0375-x · Cited by 37 · cited 2×
“A decrease in propidium fluorescence in the presence of test compounds indicates that they are able to displace propidium and bind to the PAS of AChE, suggesting that they would thereby block the AChE-mediated aggregation of β-amyloid [24,27,29,33].”
BackgroundSelf-citationUlus, R., Kurt, B. Z., Gazioğlu, I., & Kaya, M. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.01.005 · Cited by 36 · cited 3×
“The presence of antioxidant activity in a number of sulfonamide derivatives [66,68,69] prompted us to assess the antioxidant properties of the new hybrid compounds.”
BackgroundAkocak, S., Boğa, M., Lolak, N., Tuneğ, M., & Sanku, R. K. K. (2019) · Journal of the Turkish Chemical Society Section A Chemistry · doi:10.18596/jotcsa.516444 · Cited by 32 · cited 1×
“Moreover, antioxidant activity has been shown for certain sulfonamide derivatives [65,66,68,69].”
BackgroundRosini, M., Simoni, E., Bartolini, M., Soriano, E., Marco, J. L., Andrisano, V., Monti, B., Windisch, M., Hutter‐Paier, B., McClymont, D. W., et al. (2013) · ChemMedChem · doi:10.1002/cmdc.201300263 · Cited by 31
Špilovská, K., Korábečný, J., Horova, A., Musílek, K., Nepovimová, E., Drtinová, L., Gažová, Z., Šipošová, K., Doležal, R., Jun, D., et al. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1316-x · Cited by 31
Darvesh, S. (2015) · Current Alzheimer Research · doi:10.2174/156720501301151207095006 · Cited by 31
Supercomputer Modeling of Dual-Site Acetylcholinesterase (AChE) Inhibition
Lushchekina, S. V., Махаева, Г. Ф., Novichkova, D. A., Zueva, I. V., Ковалева, Н. В., & Richardson, R. J. (2018) · Supercomputing Frontiers and Innovations · doi:10.14529/jsfi180410 · Cited by 27 · cited 1×
“This structure has conformational changes of CAS and PAS amino acids necessary to accommodate bulky inhibitors [92].”
BackgroundSelf-citationChen, Y., Sun, J., Peng, S., Liao, H., Zhang, Y., & Lehmann, J. (2013) · Archiv der Pharmazie · doi:10.1002/ardp.201300074 · Cited by 25 · cited 1×
“The results are consistent with the known data that, in contrast to extremely powerful bis-tacrine inhibitors [78], tacrine-based hybrid compounds linking tacrine with an uncharged aromatic group had anti-AChE activities comparable to that of tacrine [79,80].”
ResultCzarnecka, K., Szymański, P., Girek, M. K., Mikiciuk‐Olasik, E., Skibiński, R., Kabziński, J., Majsterek, I., Malawska, B., Jończyk, J., & Bajda, M. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.05.003 · Cited by 23 · cited 1×
“The results are consistent with the known data that, in contrast to extremely powerful bis-tacrine inhibitors [78], tacrine-based hybrid compounds linking tacrine with an uncharged aromatic group had anti-AChE activities comparable to that of tacrine [79,80].”
ResultSynthesis and Anti-Oxidant Evaluation of Some Novel Sulfa Drugs
Gouda, M. A., & Hussein, B. H. M. (2017) · Letters in Drug Design & Discovery · doi:10.2174/1570180814666170607144811 · Cited by 10
Махаева, Г. Ф., Ковалева, Н. В., Lushchekina, S. V., Рудакова, Е. В., Boltneva, N. P., Proshin, A. N., Lednev, B. V., Serkov, I. V., & Бачурин, С. О. (2018) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672918060200 · Cited by 10 · cited 5×
“The activities of compounds 7b,f,i,k obtained here coincided with the previously determined results [71].”
MethodResultSelf-citationBis-γ-carbolines as new potential multitarget agents for Alzheimer’s disease
Махаева, Г. Ф., Shevtsova, E. F., Aksinenko, A. Y., Ковалева, Н. В., Boltneva, N. P., Lushchekina, S. V., Рудакова, Е. В., Pushkareva, E. A., Serkova, T. P., Dubova, L. G., et al. (2020) · Pure and Applied Chemistry · doi:10.1515/pac-2019-1206 · Cited by 10
Self-citation(1998) · doi:10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10>3.0.co;2-b
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Махаева, Г. Ф., Ковалева, Н. В., Рудакова, Е. В., Boltneva, N. P., Lushchekina, S. V., Faingold, I. I., Poletaeva, D. A., Soldatova, Y. V., Kotelnikova, R. A., Serkov, I. V., et al. (2020) · Molecules · doi:10.3390/molecules25245891 · Cited by 58
“Similar effects have been obtained for other hybrid structures based on tacrine cyclic analogs [52,75,76].”
BackgroundMethodSelf-citationМахаева, Г. Ф., Lushchekina, S. V., Ковалева, Н. В., Astakhova, T. Y., Boltneva, N. P., Рудакова, Е. В., Serebryakova, O. G., Proshin, A. N., Serkov, I. V., Трофимова, Т. П., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104974 · Cited by 57
Self-citationRadchenko, E. V., Дябина, А. С., & Palyulin, V. A. (2020) · Molecules · doi:10.3390/molecules25245901 · Cited by 56
Self-citationLitim, B., Djahoudı, A., Meliani, S., & Boukhari, A. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02815-5 · Cited by 46
“by their broad range of biological activities, such as antiAlzheimer [9], antidiabetic [10], anti-inflammatory [11],”
Background
Metadata
- Authors
- Makhaeva, G. F., Kovaleva, N. V., Boltneva, N. P., Lushchekina, S. V., Astakhova, T. Y., Rudakova, E. V., Proshin, A. N., Serkov, I. V., Radchenko, E. V., Palyulin, V. A., Bachurin, S. O., & Richardson, R. J.
- Affiliations
- Institute of Physiologically Active Compounds, Russian Academy of Sciences, 142432 Chernogolovka, Russia
- Russian Academy of Sciences (RU)
- University of Michigan (US)
- Corresponding author
- Richardson, Rudy J.
- ORCID
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-08-27
- Volume
- 25
- Issue
- 17
- Pages
- 3915
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7504258
- OpenAlex
- W3080321652
- Cited by
- 53
- References
- 113
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 6 · 2023: 10 · 2022: 6 · 2021: 6 · 2020: 4
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Russian Foundation for Basic Research (19-53-26016_a)
- IPAC RAS State Targets Project (0090-2019-0005)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- acetylcholinesterase inhibitors, butyrylcholinesterase inhibitors, Alzheimer's disease, structure-activity relationship, peripheral anionic site, amyloid-beta aggregation, ADMET prediction, molecular docking
- MeSH terms
- Alzheimer Disease, Antioxidants, Cholinesterase Inhibitors, Drug Interactions, Humans, Models, Molecular, Quinolines, Structure-Activity Relationship, Sulfonamides, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.